Forest Laboratories Inc. said Monday its potential treatment for pain associated with diabetes failed to meet key midstage study goals.
The company and its partner, Gedeon Richter PLC, said Radiprodil failed to reduce pain compared with placebo. The study focused on diabetic peripheral neuropathy, or pain associated with diabetes.
The companies said they will review the complete study database over the coming weeks to determine the appropriate next steps regarding development of the drug candidate.
Shares of Forest Laboratories rose 34 cents to close at $27.97.